Status:
TERMINATED
Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2
Lead Sponsor:
Corewell Health East
Conditions:
SARS-COV2
Severe Acute Respiratory Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this study is to evaluate if CT (Computerized Tomography) can effectively and accurately predict disease progression in patients with SARS-CoV-2 (severe acute respiratory syndrome coronavi...
Detailed Description
Beaumont Quantitative CT lung function imaging (BQLFI) uses mathematical modeling to determine regional differences in ventilation (CT-V) and pulmonary blood mass (PBM) from a pair of inspiration-expi...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Adults \>18 years of age
- Written Informed consent
- A confirmed diagnosis of SARS-CoV-2 with mild to moderate disease, on room air or supplemental oxygen not more than 12L
- Concomitant medications for the treatment are allowed
- Exclusion criteria:
- Patients \<18 years
- Pregnant females
- Invasive ventilator support or non-invasive ventilator support including high flow nasal cannula
- COPD or Congestive Heart Failure patients requiring home oxygen
- History of lung cancer and radiation to lung or had prior radiation to the chest
Exclusion
Key Trial Info
Start Date :
June 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 14 2021
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04320511
Start Date
June 24 2020
End Date
May 14 2021
Last Update
January 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beaumont Health
Royal Oak, Michigan, United States, 48073